Form 4: Protagonist CFO Exercises Options, Sells Shares

Protagonist Therapeutics' CFO Asif Ali reported exercising stock options and subsequently selling a significant number of common shares under a 10b5-1 plan.

Summary

• Asif Ali, Chief Financial Officer of Protagonist Therapeutics, Inc. (PTGX), reported transactions on January 27, 2026.
• Ali exercised stock options to acquire 16,000 shares of common stock at an exercise price of $19.19 per share.
• Additionally, Ali exercised stock options to acquire 12,000 shares of common stock at an exercise price of $12.17 per share.
• Following the option exercises, Ali disposed of 28,000 shares of common stock through sales at a weighted average price of $83.13 per share, with prices ranging from $82.77 to $83.595.
• Ali also disposed of an additional 18,203 shares of common stock through sales at a weighted average price of $83.14 per share, with prices ranging from $82.80 to $83.595.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• After these transactions, Ali beneficially owns 60,320 shares of common stock directly.
• Remaining derivative securities include 50,800 stock options with an exercise price of $19.19 and 18,547 stock options with an exercise price of $12.17.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is significant insider selling, the explicit mention of a Rule 10b5-1 plan suggests these are pre-planned transactions for diversification or liquidity, rather than a signal of negative company performance or outlook.

Positives

• The Chief Financial Officer exercised stock options at significantly lower prices ($19.19 and $12.17) compared to the sale prices (weighted average of $83.13 and $83.14), indicating a substantial gain on these transactions.

Negatives

• A significant number of shares (46,203) were sold by a key executive, which could be perceived negatively by some investors, although it was part of a pre-arranged plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details routine insider transactions for an executive at a biotechnology company. Such transactions are common for executives to manage personal finances, diversify portfolios, or realize gains from equity compensation. The use of a 10b5-1 plan indicates these were pre-scheduled, aligning with standard corporate governance practices for managing insider trading.

Stakeholder Impact

• Shareholders may observe the executive's share sales, but the 10b5-1 plan mitigates concerns about immediate negative implications for the company's stock value.
• Employees are not directly impacted by these specific transactions, though executive share activity is often monitored.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Asif Ali, CFO, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Biotechnology